[go: up one dir, main page]

PE20070333A1 - Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos - Google Patents

Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos

Info

Publication number
PE20070333A1
PE20070333A1 PE2006001068A PE2006001068A PE20070333A1 PE 20070333 A1 PE20070333 A1 PE 20070333A1 PE 2006001068 A PE2006001068 A PE 2006001068A PE 2006001068 A PE2006001068 A PE 2006001068A PE 20070333 A1 PE20070333 A1 PE 20070333A1
Authority
PE
Peru
Prior art keywords
agomelatin
treatment
pharmaceutical composition
sleep disorders
composition including
Prior art date
Application number
PE2006001068A
Other languages
English (en)
Inventor
Bruno Delalleau
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36200255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070333(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20070333A1 publication Critical patent/PE20070333A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE AGOMELATINA O N-[2-(7-METOXI-1-NAFTIL)ETIL] ACETAMIDA PARA EL TRATAMIENTO DE LOS TRANSTORNOS DEL SUENO EN EL PACIENTE DEPRIMIDO, DE MODO QUE LA AGOMELATINA NO SE COMPORTA COMO UN ANTIDEPRESIVO CLASICO SI NO QUE ACTUA RESPETANDO LA ARQUITECTURA DEL SUENO Y POR CONSIGUIENTE RESPETANDO LA REACCION HOMEOSTATICA DEL SUENO EN EL PACIENTE DEPRIMIDO
PE2006001068A 2005-09-09 2006-09-04 Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos PE20070333A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0509207A FR2890562B1 (fr) 2005-09-09 2005-09-09 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime

Publications (1)

Publication Number Publication Date
PE20070333A1 true PE20070333A1 (es) 2007-06-02

Family

ID=36200255

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001068A PE20070333A1 (es) 2005-09-09 2006-09-04 Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos

Country Status (25)

Country Link
US (1) US20070060655A1 (es)
EP (2) EP1762237A1 (es)
JP (1) JP2007077148A (es)
KR (2) KR20070029608A (es)
CN (1) CN1927193B (es)
AP (1) AP2008004379A0 (es)
AR (1) AR056063A1 (es)
AU (1) AU2006209372A1 (es)
BR (1) BRPI0603762A (es)
CA (1) CA2558762A1 (es)
EA (1) EA014288B1 (es)
FR (1) FR2890562B1 (es)
GE (1) GEP20094602B (es)
GT (1) GT200600409A (es)
MA (1) MA28506B1 (es)
MX (1) MXPA06010233A (es)
NO (1) NO20064050L (es)
NZ (1) NZ549726A (es)
PE (1) PE20070333A1 (es)
SG (1) SG146451A1 (es)
TW (1) TW200800148A (es)
UA (1) UA81573C2 (es)
UY (1) UY29777A1 (es)
WO (1) WO2007028905A1 (es)
ZA (1) ZA200607531B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918372B1 (fr) * 2007-07-02 2009-08-28 Servier Lab Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2918370B1 (fr) * 2007-07-02 2009-08-28 Servier Lab Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
CN101991559B (zh) * 2010-11-25 2012-04-18 天津市汉康医药生物技术有限公司 一种稳定的阿戈美拉汀胶囊药物组合物
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2013119605A1 (en) * 2012-02-07 2013-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Promoting sleep using at1 receptor blockers
CN102552211B (zh) * 2012-02-16 2013-07-17 福建广生堂药业股份有限公司 一种阿戈美拉汀的制剂组合物及其制备方法
EP2810656B1 (en) 2013-06-06 2017-08-02 Zentiva, a.s. Agomelatine formulations comprising agomelatine in the form of co-crystals
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EP2856934A1 (en) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression
CN103655499B (zh) * 2013-12-23 2015-07-22 天津泰普药品科技发展有限公司 一种稳定的晶x型阿戈美拉汀片剂及其制备方法
CN103690499B (zh) * 2013-12-23 2015-05-06 天津泰普药品科技发展有限公司 一种稳定的晶i型阿戈美拉汀片剂及其制备方法
CN104523639B (zh) * 2014-12-11 2017-03-22 扬子江药业集团四川海蓉药业有限公司 一种阿戈美拉汀片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
WO2005063297A2 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7635721B2 (en) * 2005-08-03 2009-12-22 Les Laboratoires Servier Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7645905B2 (en) * 2005-08-03 2010-01-12 Les Laboratoires Servier Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
AP2008004379A0 (en) 2008-04-30
UA81573C2 (en) 2008-01-10
FR2890562B1 (fr) 2012-10-12
GT200600409A (es) 2007-04-30
UY29777A1 (es) 2006-10-31
KR20080103043A (ko) 2008-11-26
JP2007077148A (ja) 2007-03-29
EA014288B1 (ru) 2010-10-29
EP1762237A1 (fr) 2007-03-14
EP2295050A1 (fr) 2011-03-16
NO20064050L (no) 2007-03-12
MA28506B1 (fr) 2007-04-03
WO2007028905A1 (fr) 2007-03-15
CN1927193A (zh) 2007-03-14
EA200601449A1 (ru) 2007-04-27
KR20070029608A (ko) 2007-03-14
FR2890562A1 (fr) 2007-03-16
CN1927193B (zh) 2011-01-05
HK1100481A1 (en) 2007-09-21
MXPA06010233A (es) 2007-03-08
TW200800148A (en) 2008-01-01
US20070060655A1 (en) 2007-03-15
ZA200607531B (en) 2008-05-28
AR056063A1 (es) 2007-09-19
NZ549726A (en) 2008-03-28
AU2006209372A1 (en) 2007-03-29
SG146451A1 (en) 2008-10-30
GEP20094602B (en) 2009-02-10
BRPI0603762A (pt) 2007-05-15
CA2558762A1 (fr) 2007-03-09

Similar Documents

Publication Publication Date Title
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
CL2011000488A1 (es) Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus.
UY32177A (es) Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
GT200600045A (es) Derivados de piridizina y su uso como agentes terapeuticos
EA201300213A1 (ru) Применение ингибиторов dpp iv
MX2009013989A (es) Terapia en combinacion para depresion.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
MX2008009583A (es) Composiciones para uso vaginal.
CR10524A (es) Compuesto triciclico y uso farmaceutico del mismo
ES2421709T3 (es) Uso de veneno de abeja para tratar la enfermedad de Parkinson
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR063896A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del sindrome de smith magenis
CR9074A (es) Agente para la profilaxis o tratamiento del sindrome metabolico
CR9426A (es) Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares
BRPI0702847A (pt) formas de dosagem unitária de temozolomida
PA8651401A1 (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
PA8806001A1 (es) Nuevo uso medico de las sales de propionato de 3-(2,2,2-trimetilhidrazinio) en el tratamiento de la enfermedad cardíaca isquémica

Legal Events

Date Code Title Description
FC Refusal